Karyopharm Therapeutics (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the stock in a transaction that occurred on Wednesday, April 18th. The stock was sold at an average price of $14.79, for a total value of $147,900.00. Following the completion of the transaction, the chief executive officer now directly owns 522,143 shares of the company’s stock, valued at $7,722,494.97. The sale was disclosed in a filing with the SEC, which is available through this link.

Michael Kauffman also recently made the following trade(s):

  • On Monday, March 19th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $15.29, for a total value of $152,900.00.
  • On Tuesday, February 20th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $14.79, for a total value of $147,900.00.

KPTI opened at $14.59 on Friday. Karyopharm Therapeutics has a 1-year low of $7.48 and a 1-year high of $18.00.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.14). The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $2.26 million. Karyopharm Therapeutics’s revenue for the quarter was up 3163.8% compared to the same quarter last year. During the same period last year, the business earned ($0.65) EPS. equities analysts anticipate that Karyopharm Therapeutics will post -2.81 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter worth approximately $146,000. Palo Alto Investors LLC lifted its position in shares of Karyopharm Therapeutics by 1.3% during the 4th quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock valued at $34,027,000 after acquiring an additional 45,854 shares during the last quarter. Millennium Management LLC lifted its position in shares of Karyopharm Therapeutics by 17.8% during the 4th quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock valued at $4,194,000 after acquiring an additional 65,920 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Karyopharm Therapeutics by 76.8% during the 4th quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock valued at $233,000 after acquiring an additional 10,520 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Karyopharm Therapeutics by 16.1% during the 4th quarter. Deutsche Bank AG now owns 188,373 shares of the company’s stock valued at $1,806,000 after acquiring an additional 26,108 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

KPTI has been the subject of a number of recent analyst reports. HC Wainwright increased their price objective on Karyopharm Therapeutics to $26.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. BidaskClub raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 9th. JPMorgan Chase increased their price objective on Karyopharm Therapeutics from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, April 10th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 21st. Finally, Royal Bank of Canada restated a “buy” rating and issued a $22.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $20.20.

WARNING: “Michael Kauffman Sells 10,000 Shares of Karyopharm Therapeutics (KPTI) Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/04/22/michael-kauffman-sells-10000-shares-of-karyopharm-therapeutics-kpti-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.